Advanced search
Publication Cover
Scandinavian Journal of Urology and Nephrology Volume 46, 2012 - Issue 5
Submit an article Journal homepage
4,543
Views
8
CrossRef citations to date
0
Altmetric
Urology

Information on pros and cons of prostate-specific antigen testing to men prior to blood draw: A study from the National Prostate Cancer Register (NPCR) of Sweden

Jon fridrikssonDepartment of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, UmeåCorrespondence[email protected]
,
Katarina GunseusDepartment of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, Umeå
&
Pär stattinDepartment of Surgery, Urology Service, Memorial Sloan-Kettering Cancer Center, New York City, USA
Pages 326-331 | Received 23 Jan 2012, Accepted 01 May 2012, Published online: 31 May 2012

References

  • Stark JR, Mucci L, Rothman KJ, Adami HO. Screening for prostate cancer remains controversial. BMJ 2009;339:b3601.
  • United States Preventive Services Task Force. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. 11 October 2011. Available from: http://www.uspreventiveservicestaskforce.org/draftrec3.htm.
  • Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Screening for prostate cancer: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2011;155:762–1.
  • Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61–71.
  • Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868–78.
  • Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725–32.
  • Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–8.
  • Sheridan SL, Felix K, Pignone MP, Lewis CL. Information needs of men regarding prostate cancer screening and the effect of a brief decision aid. Patient Educ Couns 2004;54:345–51.
  • Watson E, Hewitson P, Brett J, Bukach C, Evans R, Edwards A, Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested. Patient Educ Couns 2006;63:367–79.
  • Volk RJ, Hawley ST, Kneuper S, Holden EW, Stroud LA, Cooper CP, Trials of decision aids for prostate cancer screening: a systematic review. Am J Prev Med 2007;33:428–34.
  • Evans R, Edwards A, Brett J, Bradburn M, Watson E, Austoker J, Reduction in uptake of PSA tests following decision aids: systematic review of current aids and their evaluations. Patient Educ Couns 2005;58:13–26.
  • Frosch DL, Kaplan RM, Felitti V. The evaluation of two methods to facilitate shared decision making for men considering the prostate-specific antigen test. J Gen Intern Med 2001;16:391–8.
  • Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber J-E, Hellström M, The National Prostate Cancer Register in Sweden 1998/2002: Trends in incidence, treatment and survival. Scand J Urol Nephrol 2005;39:117–23.
  • Stattin P, Holmberg E, Bratt O, Adolfsson J, Johansson J-E, Hugosson J. Surveillance and Deferred Treatment for Localized Prostate Cancer. Population Based Study in the National Prostate Cancer Register of Sweden. J Urol 2008;180:2423–30.
  • Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009;48:27–33.
  • Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andrén O, Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007;41:456–77.
  • Regionalt Cancercentrum Uppsala Örebro. Available from: www.roc.se.
  • Socialstyrelsen, editor. Nationella riktlinjer för prostatacancersjukvård Medicinskt och hälsoekonomiskt faktadokument. Lindesberg: Bergslagens Grafiska; 2007. p 22–35.
  • Socialstyrelsen, editor. Om PSA-prov för att kunna upptäcka prostatacancer i ett tidigt skede – fördelar och nackdelar. Västerås: Edita Västra Aros; 2010.
  • Schapira MM, VanRuiswyk J. The effect of an illustrated pamphlet decision-aid on the use of prostate cancer screening tests. J Fam Pract 2000;49:418–24.
  • Hoffman RM, Couper MP, Zikmund-Fisher BJ, Levin CA, McNaughton-Collins M, Helitzer DL, Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). Arch Intern Med 2009;169:1611–18.
  • Bowen DJ, Hannon PA, Harris JR, Martin DP. Prostate cancer screening and informed decision-making: provider and patient perspectives. Prostate Cancer Prostatic Dis 2011;14:155–61.
  • Partin MR, Nelson D, Flood AB, Friedemann-Sanchez G, Wilt TJ. Who uses decision aids? Subgroup analyses from a randomized controlled effectiveness trial of two prostate cancer screening decision support interventions. Health Expect 2006;9:285–95.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.